SG11202001008RA - Preparation of therapeutic exosomes using membrane proteins - Google Patents

Preparation of therapeutic exosomes using membrane proteins

Info

Publication number
SG11202001008RA
SG11202001008RA SG11202001008RA SG11202001008RA SG11202001008RA SG 11202001008R A SG11202001008R A SG 11202001008RA SG 11202001008R A SG11202001008R A SG 11202001008RA SG 11202001008R A SG11202001008R A SG 11202001008RA SG 11202001008R A SG11202001008R A SG 11202001008RA
Authority
SG
Singapore
Prior art keywords
preparation
membrane proteins
therapeutic exosomes
exosomes
therapeutic
Prior art date
Application number
SG11202001008RA
Other languages
English (en)
Inventor
Kevin Dooley
Rane Harrison
Russell Mcconnell
Ke Xu
Damian Houde
Nikki Ross
Sonya Haupt
John Kulman
Douglas Williams
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of SG11202001008RA publication Critical patent/SG11202001008RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202001008RA 2017-08-25 2018-08-24 Preparation of therapeutic exosomes using membrane proteins SG11202001008RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550543P 2017-08-25 2017-08-25
US201862656956P 2018-04-12 2018-04-12
PCT/US2018/048026 WO2019040920A1 (en) 2017-08-25 2018-08-24 PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS

Publications (1)

Publication Number Publication Date
SG11202001008RA true SG11202001008RA (en) 2020-03-30

Family

ID=65200359

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001008RA SG11202001008RA (en) 2017-08-25 2018-08-24 Preparation of therapeutic exosomes using membrane proteins

Country Status (15)

Country Link
US (4) US10195290B1 (es)
EP (1) EP3672573A4 (es)
JP (2) JP2020531018A (es)
KR (2) KR20240033086A (es)
CN (2) CN118374452A (es)
AU (1) AU2018321927A1 (es)
BR (1) BR112020003354A2 (es)
CA (1) CA3072352A1 (es)
CL (1) CL2020000428A1 (es)
CO (1) CO2020001872A2 (es)
IL (1) IL272786A (es)
MX (1) MX2020001790A (es)
PH (1) PH12020500308A1 (es)
SG (1) SG11202001008RA (es)
WO (1) WO2019040920A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672573A4 (en) 2017-08-25 2021-05-26 Codiak BioSciences, Inc. PRODUCTION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
EA202091134A1 (ru) * 2017-12-28 2020-11-20 Кодиак Байосайенсес, Инк. Экзосомы для иммуноонкологической и противовоспалительной терапии
EP3752615A1 (en) 2018-02-12 2020-12-23 Codiak BioSciences, Inc. Methods and compositions for macrophage polarization
SG11202008636YA (en) * 2018-03-23 2020-10-29 Codiak Biosciences Inc Extracellular vesicles comprising sting-agonist
WO2019246591A1 (en) 2018-06-21 2019-12-26 Codiak Biosciences, Inc. Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering
WO2020041720A1 (en) 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
WO2020072699A1 (en) * 2018-10-02 2020-04-09 Exosome Therapeutics, Inc. Exosome loaded therapeutics for treating sickle cell disease
US20240076669A1 (en) * 2018-10-02 2024-03-07 Exosome Therapeutics, Inc. cGMP EXOSOME LOADED THERAPEUTICS FOR TREATING SICKLE CELL DISEASE
HRP20220020T1 (hr) 2018-11-16 2022-04-01 Codiak Biosciences, Inc. Modificirane izvanstanične vezikule i njihova uporaba
US20220144942A1 (en) 2019-02-04 2022-05-12 Codiak Biosciences, Inc. Treatment of cancer metastasis by targeting exosome proteins
WO2020163370A1 (en) 2019-02-04 2020-08-13 Codiak Biosciences, Inc. Membrane protein scaffolds for exosome engineering
EP3941528A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Extracellular vesicle conjugates and uses thereof
CN114080232A (zh) 2019-03-21 2022-02-22 科迪亚克生物科学公司 用于疫苗递送的细胞外囊泡
US20220387906A1 (en) 2019-03-21 2022-12-08 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2020191392A1 (en) * 2019-03-21 2020-09-24 Applied Stemcell, Inc. Exosomes containing rna with specific mutation
WO2020214961A1 (en) * 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Methods of treating tuberculosis
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
EP3974518A4 (en) * 2019-05-21 2023-06-21 H.U. Group Research Institute G.K. PROCEDURE FOR WASHING EXTRACELLULAR VESICLE
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
WO2021003425A1 (en) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Methods of inducing hematopoiesis
US20210093567A1 (en) * 2019-08-06 2021-04-01 Ohio State Innovation Foundation Therapeutic extracellular vesicles
JP2022544935A (ja) 2019-08-14 2022-10-24 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞－ｎｌｒｐ３アンタゴニスト
EP4013877A1 (en) 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting stat6
US20220354963A1 (en) 2019-08-14 2022-11-10 Codiak Biosciences, Inc. Extracellular vesicle linked to molecules and uses thereof
CA3147369A1 (en) 2019-08-14 2021-02-18 Dalia BURZYN Extracellular vesicle-aso constructs targeting cebp/beta
JP2022544934A (ja) 2019-08-14 2022-10-24 コディアック バイオサイエンシーズ， インコーポレイテッド Ｓｔａｔ３－アンチセンスオリゴヌクレオチドを含む細胞外小胞
JP2022544290A (ja) 2019-08-14 2022-10-17 コディアック バイオサイエンシーズ， インコーポレイテッド Ｋｒａｓを標的とするアンチセンスオリゴヌクレオチドを有する細胞外小胞
WO2021041473A1 (en) * 2019-08-27 2021-03-04 The Trustees Of Columbia University In The City Of New York Engineered exosomes for targeted delivery
EP4034081A1 (en) * 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Extracellular vesicle compositions
WO2021062058A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021062290A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
WO2021062057A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Exogenous loading of exosomes via lyophilization
KR20220094221A (ko) 2019-09-25 2022-07-05 코디악 바이오사이언시즈, 인크. 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀
JP7402491B2 (ja) * 2019-10-24 2023-12-21 国立大学法人広島大学 エクソソームの単離方法、エクソソームの単離キット、およびエクソソームの除去方法
US20220390437A1 (en) 2019-11-05 2022-12-08 Codiak Biosciences, Inc. High-throughput chromatography screening for extracellular vesicles
TWI787697B (zh) * 2019-12-30 2022-12-21 財團法人工業技術研究院 外泌體的分離方法、膠體粒子及其製備方法
EP4090974A1 (en) 2020-01-17 2022-11-23 Codiak BioSciences, Inc. Cholesterol assays for quantifying extracellular vesicles
US20230097907A1 (en) * 2020-01-27 2023-03-30 Mantra Bio, Inc. Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof
AU2021215935A1 (en) 2020-02-05 2022-08-25 Diadem Biotherapeutics Inc. Artificial synapses
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
CA3171143A1 (en) * 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Targeted delivery of extracellular vesicles
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
WO2021189047A2 (en) 2020-03-20 2021-09-23 Codiak Biosciences, Inc. Extracellular vesicles for therapy
US20230143893A1 (en) * 2020-03-23 2023-05-11 Avem Holdings Llc Isolation and purification of exosomes for regenerative medicine
EP4150054A1 (en) 2020-05-11 2023-03-22 Sterm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2021248133A1 (en) 2020-06-05 2021-12-09 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
JP2023538077A (ja) 2020-08-17 2023-09-06 コディアック バイオサイエンシーズ， インコーポレイテッド がんの治療方法
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US20230366794A1 (en) 2020-09-23 2023-11-16 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
US20230364127A1 (en) 2020-10-06 2023-11-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN113252616B (zh) * 2021-01-29 2022-05-03 厦门大学 一种外泌体的糖基化研究方法
EP4294456A1 (en) 2021-02-17 2023-12-27 Lonza Sales AG Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
CA3207944A1 (en) 2021-02-17 2022-08-25 Ajay Verma Extracellular vesicle-nlrp3 antagonist
IL305172A (en) 2021-02-17 2023-10-01 Lonza Sales Ag Methods for loading extracellular vesicles
JP2024513841A (ja) 2021-04-01 2024-03-27 ロンザ セールス アーゲー 細胞外小胞組成物
JP2024514156A (ja) * 2021-04-14 2024-03-28 アンジャリウム バイオサイエンシズ エージー Ｆｃ由来のポリペプチド
AU2022315530A1 (en) 2021-07-20 2024-01-18 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023027082A1 (ja) * 2021-08-23 2023-03-02 積水化学工業株式会社 ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
KR20240082391A (ko) 2021-10-14 2024-06-10 론자 세일즈 아게 세포외 소포 생산을 위한 변형된 생산자 세포
CN113832003A (zh) * 2021-10-20 2021-12-24 上海芙普瑞生物科技有限公司 一种便于提取制备脂肪干细胞外泌体的设备及提取工艺
KR20240099481A (ko) * 2021-11-16 2024-06-28 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 건 복구를 위한 조성물 및 방법
WO2023127645A1 (ja) * 2021-12-28 2023-07-06 積水化学工業株式会社 エクソソーム、それを形成するための方法、及びそれを含有する組成物
CN114112867A (zh) * 2022-01-26 2022-03-01 天九再生医学(天津)科技有限公司 外泌体纯度分析方法
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023229366A1 (en) * 2022-05-24 2023-11-30 Shiftbio Co., Ltd. Surface-engineered extracellular vesicles and therapeutic uses thereof
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
CN117802045A (zh) * 2022-09-30 2024-04-02 北京恩康医药有限公司 一种工程化细胞外囊泡的构建及其应用
WO2024065651A1 (zh) * 2022-09-30 2024-04-04 谛邈生物科技（新加坡）有限公司 一种向adam10基因敲除的hek293细胞外泌体中装载二聚体cd24的方法
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024112359A1 (en) * 2022-11-21 2024-05-30 The Johns Hopkins University Genetic enhancement of exosome production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747660A (en) 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
WO2001093836A2 (en) 2000-06-09 2001-12-13 Teni Boulikas Encapsulation of polynucleotides and drugs into targeted liposomes
US20040049010A1 (en) 2001-10-26 2004-03-11 Warren Bridget A Transmembrane proteins
US7803906B2 (en) 2002-03-22 2010-09-28 Gene Signal International Sa Composition comprising an angiogenesis related protein
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2012048372A1 (en) 2010-10-11 2012-04-19 Medsaic Pty Ltd Assay for disease detection
US9777042B2 (en) * 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
AU2013347838A1 (en) * 2012-11-26 2015-06-11 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
EP3825401A1 (en) * 2012-12-12 2021-05-26 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
EP2970914B1 (en) 2013-03-13 2019-07-03 The University of Queensland A method of isolating cells for therapy and prophylaxis
KR20150043937A (ko) 2013-10-15 2015-04-23 삼성전자주식회사 개체의 간암 진단용 조성물, 개체의 간암 진단하는 방법 및 개체의 간암 진단에 필요한 정보를 얻는 방법
CN116731958A (zh) 2014-10-09 2023-09-12 细胞结构公司 胎盘来源的贴壁细胞外泌体及其用途
WO2016077639A2 (en) * 2014-11-12 2016-05-19 VL27, Inc. Nanovesicular therapies
WO2017075708A1 (en) * 2015-11-05 2017-05-11 Exerkine Corporation Exosomes useful to treat cystic fibrosis
WO2017117585A1 (en) 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
MX2018011202A (es) 2016-03-15 2019-03-28 Codiak Biosciences Inc Vesiculas de membrana terapeuticas.
US20200113943A1 (en) 2017-06-05 2020-04-16 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage
EP3672573A4 (en) 2017-08-25 2021-05-26 Codiak BioSciences, Inc. PRODUCTION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS

Also Published As

Publication number Publication date
WO2019040920A1 (en) 2019-02-28
JP2023160981A (ja) 2023-11-02
US20190117792A1 (en) 2019-04-25
US11679164B2 (en) 2023-06-20
US20190060483A1 (en) 2019-02-28
EP3672573A1 (en) 2020-07-01
IL272786A (en) 2020-04-30
PH12020500308A1 (en) 2021-02-08
US10195290B1 (en) 2019-02-05
AU2018321927A1 (en) 2020-02-27
MX2020001790A (es) 2020-07-22
CN118374452A (zh) 2024-07-23
CO2020001872A2 (es) 2020-06-19
EP3672573A4 (en) 2021-05-26
JP2020531018A (ja) 2020-11-05
CA3072352A1 (en) 2019-02-28
US20200222556A1 (en) 2020-07-16
US20240009322A1 (en) 2024-01-11
BR112020003354A2 (pt) 2020-08-18
KR20240033086A (ko) 2024-03-12
CN111212632A (zh) 2020-05-29
KR20200071065A (ko) 2020-06-18
CN111212632B (zh) 2024-04-16
CL2020000428A1 (es) 2020-11-27
US10561740B2 (en) 2020-02-18
WO2019040920A8 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
IL272786A (en) Preparation of therapeutic exosomes using membrane proteins
ZA201807945B (en) Exosomes comprising therapeutic polypeptides
IL261490A (en) Medical membrane vesicles
EP3548005A4 (en) EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
IL256515A (en) Therapeutic peptides and methods of use thereof
FR3018450B1 (fr) Procede de preparation de proteines plasmatiques humaines
EP3220953A4 (en) COMPOSITIONS AND METHODS OF USING THERAPEUTIC p53 PEPTIDES AND ANALOGUES
EP3116898A4 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
IL247368A0 (en) Diagnostic and therapeutic uses of exosomes
HK1256033A1 (zh) 用於刺激免疫系統的肽
HK1256712A1 (zh) P75ntr神經營養因子結合蛋白的治療性用途
HK1249068A1 (zh) 小檗碱製劑的治療用途
ZA201902689B (en) Therapeutic protein
IL262907B1 (en) Using amino sugar as a plasticizer
ZA201906326B (en) Analogs of deutetrabenazine, their preparation and use
EP3313427A4 (en) Therapeutic peptides and methods of use thereof
EP3538541A4 (en) MANUFACTURING AND USE OF GINSENTIDES AND GINSENTID-LIKE PEPTIDES
EP3204768A4 (en) High resolution imaging of tissue proteins
EP3393493A4 (en) INFANT NUTRITION WITH MOTHER'S MILK PEPTIDES
EP3325496C0 (en) METHOD FOR PRODUCING A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE
GB201703033D0 (en) Detection of membrane proteins
HK1256714A1 (zh) 製備治療性蛋白質的方法
EP3615561C0 (en) VARIANTS OF HUMAN BMP7 PROTEIN
PL3202393T3 (pl) Śródskórne podawanie preparatu immunoglobuliny g
GB201714566D0 (en) Protein delivery to membranes